Topkan E, et al. - Researchers examined survival in relation to prolonged overall radiotherapy duration (ORTD) among 956 patients who underwent concurrent chemoradiotherapy for stage IIIB/C non-small-cell lung cancers. This retrospective but largest-to-date single institutional cohort analysis revealed significantly poorer overall survival, locoregional progression-free survival and progression-free survival outcomes in correlation to longer ORTD beyond ≥50 days, where reduced locoregional control rates appeared to be the main causative.